1043890-91-0

Upstream product

• 63328-49-4 (R)-2-amino-6-tert-butoxycarbonylaminohexanoic acid methyl ester 
• 1043890-88-5 (R)-6-tert-butoxycarbonylamino-2-(4-fluoro-3,5-dimethylphenylamino)hexanoic acid methyl ester 
• 342636-66-2 (4-fluoro-3,5-dimethylphenyl)boronic acid 
• 135427-08-6 4-fluoro-3-methylbenzaldehyde 
• 1043890-89-6 (R)-6-amino-2-(4-fluoro-3,5-dimethylphenylamino)hexanoic acid methyl ester 

Downstream Products

• 1043890-17-0 (R)-2-(4-fluoro-3,5-dimethylphenylamino)-6-(4-fluoro-3-methylbenzylamino)-N-hydroxyhexanamide 

Relevant academic research and scientific papers

Antidotes to anthrax lethal factor intoxication. Part 1: Discovery of potent lethal factor inhibitors with in vivo efficacy

Sub-nanomolar small molecule inhibitors of anthrax lethal factor have been identified using SAR and Merck L915 (4) as a model compound. One of these compounds (16) provided 100% protection in a rat lethal toxin model of anthrax disease.

HYDROXAMIC ACID DERIVATIVES OF ANILINE USEFUL AS THERAPEUTIC AGENTS FOR TREATING ANTHRAX POISONING

Compounds having the formula (I), wherein the symbols have the meaning described in the specification are hydroxamic acid derivatives of aniline and capable of inhibiting the lethal effects of infection by anthrax bacteria and are useful in the treatment of poisoning by anthrax.